Dissecting the link between PD-1/PD-L1-based immunotherapy and cancer pain: mechanisms, research implications, and artificial intelligence perspectives

Abstract

Cancer-related pain represents one of the most common complaints of cancer patients especially for those with advanced-stage of disease and/or bone metastases. More effective therapeutic strategies are needed not only to improve the survival of cancer patients but also to relieve cancer-related pain. In the last decade, immune checkpoint inhibitor (ICI)-based immunotherapy targeting programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) has revolutionized cancer care. Beyond its anticancer role, PD-1/PD-L1 axis pathway is involved in many other physiological processes. PD-L1 expression is found in both malignant tissues and normal tissues including the dorsal root ganglion, and spinal cord. Through its interaction with PD-1, PD-L1 can modulate neuron excitability, leading to the suppression of inflammatory, neuropathic, and bone cancer pain. Therefore, since the intricate relationship between immunotherapy and pain should be largely dissected, this comprehensive review explores the complex relationship between PD-1/PD-L1-based immunotherapy and cancer-related pain. It delves into the potential mechanisms through which PD-1/PD-L1 immunotherapy might modulate pain pathways, including neuroinflammation, neuromodulation, opioid mechanisms, and bone processes. Understanding these mechanisms is crucial for developing future research directions in order to optimize pain management strategies in cancer patients. Finally, this article discusses the role of artificial intelligence (AI) in advancing research and clinical practice in this context. AI-based strategies, such as analyzing large datasets and creating predictive models, can identify patterns and correlations between PD-1/PD-L1 immunotherapy and pain. These tools can assist healthcare providers in tailoring treatment plans and pain management strategies to individual patients, ultimately improving outcomes and quality of life for those undergoing PD-1/PD-L1-based immunotherapy.

Keywords

Immunotherapy / pain / cancer / PD-1/PD-L1 / artificial intelligence / machine learning / neuroinflammation

References

[1] Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013; 39: 1-10.

[2] Zhao J, Huh Y, Bortsov A, Diatchenko L, Ji RR. Immunotherapies in chronic pain through modulation of neuroimmune interactions. Pharmacol Ther. 2023; 248: 108476.

[3] Gupta S, Viotti A, Eichwald T, Roger A, Kaufmann E, Othman R, et al. Navigating the blurred path of mixed neuroimmune signaling. J Allergy Clin Immunol. 2024; 153: 924-38.

[4] Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020; 161: 1976-82.

[5] van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016; 51: 1070-90.e9.

[6] Javed SA, Najmi A, Ahsan W, Zoghebi K. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front Immunol. 2024; 15: 1383456.

[7] Liu W, Zhang Q, Zhang T, Li L, Xu C. Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis. World J Surg Oncol. 2022; 20: 333.

[8] Nishijima TF, Shachar SS, Muss HB, Tamura K. Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis. Oncologist. 2019; 24: e565-73.

[9] Mardelle U, Bretaud N, Daher C, Feuillet V. From pain to tumor immunity: influence of peripheral sensory neurons in cancer. Front Immunol. 2024; 15: 1335387.

[10] Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, et al. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med. 2024; 30: 1330-8.

[11] Zou D, Wang X, Sun Y, Wang X, Lu C, Wang A, et al. Arthralgia adverse events due to immune-checkpoint inhibitors for lung cancer patients: a systematic review and meta-analysis. Front Oncol. 2023; 13: 1258287.

[12] Deng D, Zhang T, Ma L, Zhao W, Huang S, Wang K, et al. PD-L1/PD-1 pathway: a potential neuroimmune target for pain relief. Cell Biosci. 2024; 14: 51.

[13] Wang R, He S, Long J, Wang Y, Jiang X, Chen M, et al. Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways. Exp Hematol Oncol. 2024; 13: 46.

[14] Nishimura H, Honjo T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 2001; 22: 265-8.

[15] Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001; 2: 261-8.

[16] Jiang C, Wang Z, Donnelly CR, Wang K, Andriessen AS, Tao X, et al. PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia. iScience. 2020; 23: 101570.

[17] Zhao L, Luo H, Ma Y, Zhu S, Wu Y, Lu M, et al. An analgesic peptide H-20 attenuates chronic pain via the PD-1 pathway with few adverse effects. Proc Natl Acad Sci U S A. 2022; 119: e2204114119.

[18] Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800.

[19] Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003; 9: 562-7.

[20] Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016; 9: 5023-39.

[21] Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nunès JA, et al. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int Immunol. 2010; 22: 651-60.

[22] Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med. 2000; 192: 1027-34.

[23] Frydenlund N, Mahalingam M. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. Hum Pathol. 2017; 66: 13-33.

[24] Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol. 2015; 33: 1974-82.

[25] Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009; 206: 3015-29.

[26] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12: 252-64.

[27] Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022; 21: 28.

[28] Golonko A, Pienkowski T, Swislocka R, Orzechowska S, Marszalek K, Szczerbinski L, et al. Dietary factors and their influence on immunotherapy strategies in oncology: a comprehensive review. Cell Death Dis. 2024; 15: 254.

[29] Malczewski AB, Ketheesan N, Coward JIG, Navarro S. Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites. Front Immunol. 2021; 12: 624434.

[30] Ferrere G, Tidjani Alou M, Liu P, Goubet AG, Fidelle M, Kepp O, et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 2021; 6: e145207.

[31] Woodall MJ, Neumann S, Campbell K, Pattison ST, Young SL. The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy. Cancers (Basel). 2020; 12: 1230.

[32] Deshpande RP, Sharma S, Watabe K. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers (Basel). 2020; 12: 2983.

[33] de With M, Hurkmans DP, Oomen-de Hoop E, Lalouti A, Bins S, El Bouazzaoui S, et al. Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy . Cancers (Basel). 2021; 13: 1370.

[34] Chin IS, Khan A, Olsson-Brown A, Papa S, Middleton G, Palles C. Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity. NPJ Genom Med. 2022; 7: 73.

[35] Polcaro G, Liguori L, Manzo V, Chianese A, Donadio G, Caputo A, et al. rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC. Mol Cancer. 2024; 23: 63.

[36] Chen G, Kim YH, Li H, Luo H, Liu DL, Zhang ZJ, et al. PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. Nat Neurosci. 2017; 20: 917-26.

[37] Shi S, Han Y, Wang D, Guo P, Wang J, Ren T, et al. PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model. Cephalalgia. 2020; 40: 288-98.

[38] Xia Q, Zhao Y, Dong H, Mao Q, Zhu L, Xia J, et al. Progress in the study of molecular mechanisms of intervertebral disc degeneration. Biomed Pharmacother. 2024; 174: 116593.

[39] Wani I, Koppula S, Balda A, Thekkekkara D, Jamadagni A, Walse P, et al. An Update on the Potential of Tangeretin in the Management of Neuroinflammation-Mediated Neurodegenerative Disorders. Life (Basel). 2024; 14: 504.

[40] Cascella M, Di Napoli R, Carbone D, Cuomo GF, Bimonte S, Muzio MR. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives. Recenti Prog Med. 2018; 109: 523-30.

[41] Cascella M, Bimonte S. The role of general anesthetics and the mechanisms of hippocampal and extra-hippocampal dysfunctions in the genesis of postoperative cognitive dysfunction. Neural Regen Res. 2017; 12: 1780-5.

[42] Bai L, Wang X, Li Z, Kong C, Zhao Y, Qian JL, et al. Upregulation of Chemokine CXCL12 in the Dorsal Root Ganglia and Spinal Cord Contributes to the Development and Maintenance of Neuropathic Pain Following Spared Nerve Injury in Rats. Neurosci Bull. 2016; 32: 27-40.

[43] Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov. 2014; 13: 533-48.

[44] Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science. 2016; 354: 572-7.

[45] Yu J, Wong S, Lin Z, Shan Z, Fan C, Xia Z, et al. High-Frequency Spinal Stimulation Suppresses Microglial Kaiso-P2X7 Receptor Axis-Induced Inflammation to Alleviate Neuropathic Pain in Rats. Ann Neurol. 2024; 95: 966-83.

[46] Li X, Wang J, Liao C, Yang X, Zhao Z, Liu Y, et al. The binding of PKCε and MEG2 to STAT3 regulates IL-6-mediated microglial hyperalgesia during inflammatory pain. FASEB J. 2024; 38: e23590.

[47] Ji RR, Berta T, Nedergaard M. Glia and pain: Is chronic pain a gliopathy? Pain. 2013; 154 Suppl 1: S10-28.

[48] Tan H, Ding Z, Zhang C, Yan J, Yang Y, Li P. The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines. Anesth Analg. 2021; 133: 1321-30.

[49] He H, Zhou Y, Zhou Y, Zhuang J, He X, Wang S, et al. Dexmedetomidine Mitigates Microglia-Mediated Neuroinflammation through Upregulation of Programmed Cell Death Protein 1 in a Rat Spinal Cord Injury Model. J Neurotrauma. 2018; 35: 2591-603.

[50] Malcangio M. Role of the immune system in neuropathic pain. Scand J Pain. 2019; 20: 33-7.

[51] Haroun R, Wood JN, Sikandar S. Mechanisms of cancer pain. Front Pain Res (Lausanne). 2023; 3: 1030899.

[52] Hirth M, Gandla J, Kuner R. A checkpoint to pain. Nat Neurosci. 2017; 20: 897-9.

[53] Zhao L, Ma Y, Song X, Wu Y, Jin P, Chen G. PD-1: A New Candidate Target for Analgesic Peptide Design. J Pain. 2023; 24: 1142-50.

[54] Berger AA, Liu Y, Possoit H, Rogers AC, Moore W, Gress K, et al. Dorsal Root Ganglion (DRG) and Chronic Pain. Anesth Pain Med. 2021; 11: e113020.

[55] Cascella M, Muzio MR. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. J Integr Med. 2017; 15: 77-87.

[56] Wanderley CWS, Maganin AGM, Adjafre B, Mendes AS, Silva CEA, Quadros AU, et al. PD-1/PD-L1 Inhibition Enhances Chemotherapy-Induced Neuropathic Pain by Suppressing Neuroimmune Antinociceptive Signaling. Cancer Immunol Res. 2022; 10: 1299-308.

[57] Cascella M, Muzio MR, Monaco F, Nocerino D, Ottaiano A, Perri F, et al. Pathophysiology of Nociception and Rare Genetic Disorders with Increased Pain Threshold or Pain Insensitivity. Pathophysiology. 2022; 29: 435-52.

[58] Kukushkin NV, Tabassum T, Carew TJ. Precise timing of ERK phosphorylation/dephosphorylation determines the outcome of trial repetition during long-term memory formation. Proc Natl Acad Sci U S A. 2022; 119: e2210478119.

[59] Xu X, Fu S, Shi X, Liu R. Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats. Pain Res Manag. 2019; 2019: 5948686.

[60] Rupniak NMJ, Perdona E, Griffante C, Cavallini P, Sava A, Ricca DJ, et al. Affinity, potency, efficacy, and selectivity of neurokinin A analogs at human recombinant NK2 and NK1 receptors. PLoS One. 2018; 13: e0205894.

[61] Lambert DG. Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis. BJA Open. 2023; 6: 100141.

[62] Meqbil YJ, Aguilar J, Blaine AT, Chen L, Cassell RJ, Pradhan AA, et al. Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype . J Pharmacol Exp Ther. 2024; 389: 301-9.

[63] Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012; 6: 11-6.

[64] Wang Z, Jiang C, He Q, Matsuda M, Han Q, Wang K, et al. Anti-PD-1 treatment impairs opioid antinociception in rodents and nonhuman primates. Sci Transl Med. 2020; 12: eaaw6471.

[65] Cornwell WD, Sriram U, Seliga A, Zuluaga-Ramirez V, Gajghate S, Rom S, et al. Tobacco smoke and morphine alter peripheral and CNS inflammation following HIV infection in a humanized mouse model. Sci Rep. 2020; 10: 13977.

[66] Scheff NN, Nilsen ML, Li J, Harris AL, Acharya R, Swartz A, et al. The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2023; 140: 106363.

[67] Ju M, Gao Z, Liu X, Zhou H, Wang R, Zheng C, et al. The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2023; 149: 2699-708.

[68] Botticelli A, Cirillo A, Pomati G, Cerbelli B, Scagnoli S, Roberto M, et al. The role of opioids in cancer response to immunotherapy. J Transl Med. 2021; 19: 119.

[69] Jimenez-Andrade JM, Mantyh WG, Bloom AP, Ferng AS, Geffre CP, Mantyh PW. Bone cancer pain. Ann N Y Acad Sci. 2010; 1198: 173-81.

[70] Zhou X, Qiao G, Ren J, Wang X, Wang S, Zhu S, et al. Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. Pain. 2020; 161: 127-34.

[71] Wang K, Gu Y, Liao Y, Bang S, Donnelly CR, Chen O, et al. PD-1 blockade inhibits osteoclast formation and murine bone cancer pain. J Clin Invest. 2020; 130: 3603-20.

[72] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 337-42.

[73] Zhao J, Bang S, Furutani K, McGinnis A, Jiang C, Roberts A, et al. PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior. Neuron. 2023; 111: 2709-26.e9.

[74] Di Lorenzo G, Melluso M, Rodolico A. What Evidence-Based Medicine (EBM) doesn’t say about allergen-specific immunotherapy (AIT). Transl Med UniSa. 2023; 25: 1-10.

[75] Wolff AC, Dresselhuis A, Hejazi S, Dixon D, Gibson D, Howard AF, et al. Healthcare provider characteristics that influence the implementation of individual-level patient-centered outcome measure (PROM) and patient-reported experience measure (PREM) data across practice settings: a protocol for a mixed methods systematic review with a narrative synthesis. Syst Rev. 2021; 10: 169.

[76] Weldring T, Smith SM. Article Commentary: Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013; 6: 61-8.

[77] Benson T. Why it is hard to use PROMs and PREMs in routine health and care. BMJ Open Qual. 2023; 12: e002516.

[78] Smith H, Downer J, Ives J. Clinicians and AI use: where is the professional guidance? J Med Ethics. 2024; 50: 437-41.

[79] Cascella M, Semeraro F, Montomoli J, Bellini V, Piazza O, Bignami E. The Breakthrough of Large Language Models Release for Medical Applications: 1-Year Timeline and Perspectives. J Med Syst. 2024; 48: 22.

[80] Sahoo SS, Plasek JM, Xu H, Uzuner Ö, Cohen T, Yetisgen M, et al. Large language models for biomedicine: foundations, opportunities, challenges, and best practices. J Am Med Inform Assoc. 2024; 31: 2114-24.

[81] Kim W, Cho YA, Kim DC, Jo AR, Min KH, Lee KE. Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models. Cancers (Basel). 2021; 13: 5465.

[82] Heilbroner SP, Few R, Mueller J, Chalwa J, Charest F, Suryadevara S, et al. Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. J Immunother Cancer. 2021; 9: e002545.

[83] Kim W, Cho YA, Min KH, Kim DC, Lee KE. Machine Learning Approaches for Assessing Risk Factors of Adrenal Insufficiency in Patients Undergoing Immune Checkpoint Inhibitor Therapy. Pharmaceuticals (Basel). 2023; 16: 1097.

[84] Noll E, Noll-Burgin M, Bonnomet F, Reiter-Schatz A, Gourieux B, Bennett-Guerrero E, et al. Knowledge-based, computerized, patient clinical decision support system for perioperative pain, nausea and constipation management: a clinical feasibility study. J Clin Monit Comput. 2024; 38: 907-13.

[85] Cascella M, Cascella A, Monaco F, Shariff MN. Envisioning gamification in anesthesia, pain management, and critical care: basic principles, integration of artificial intelligence, and simulation strategies. J Anesth Analg Crit Care. 2023; 3: 33.

[86] Cai H, Chen W, Jiang J, Wen H, Luo X, Li J, et al. Artificial Intelligence-Assisted Optimization of Antipigmentation Tyrosinase Inhibitors: De Novo Molecular Generation Based on a Low Activity Lead Compound . J Med Chem. 2024; 67: 7260-75.

[87] Zhou Z, Liao Q, Wei J, Zhuo L, Wu X, Fu X, et al. Revisiting drug-protein interaction prediction: a novel global-local perspective. Bioinformatics. 2024; 40: btae271.

[88] ArgusLab.com [Software]. Medio Systems Inc; [cited 2024 Apr 27]. Available from: http://www.arguslab.com/arguslab.com/ArgusLab.html

[89] Improta G, De Luca V, Illario M, Triassi M. Digital innovation in healthcare: a device with a method for monitoring, managing and preventing the risk of chronic polypathological patients. Transl Med UniSa. 2020; 21: 61-4.

[90] Astărăstoae V, Rogozea LM, Leaşu F, Ioan BG. Ethical Dilemmas of Using Artificial Intelligence in Medicine. Am J Ther. 2024; 31: e388-97.

[91] Dantas C, Machado N, Ortet S, Leandro F, Burnard M, Grünloh C, et al. The Iterative Model of Ethical Analysis for Large-Scale Implementation of ICT Solutions. Transl Med UniSa. 2020; 23: 1-9.